ATE509925T1 - Substituierte bicyclocarbonsäureamidverbindungen - Google Patents

Substituierte bicyclocarbonsäureamidverbindungen

Info

Publication number
ATE509925T1
ATE509925T1 AT07825705T AT07825705T ATE509925T1 AT E509925 T1 ATE509925 T1 AT E509925T1 AT 07825705 T AT07825705 T AT 07825705T AT 07825705 T AT07825705 T AT 07825705T AT E509925 T1 ATE509925 T1 AT E509925T1
Authority
AT
Austria
Prior art keywords
bicyclocarbonic
substituted
acid amide
amide compounds
compounds
Prior art date
Application number
AT07825705T
Other languages
German (de)
English (en)
Inventor
Andrew Antony Calabrese
Matthew Alexander James Duncton
Kentaro Futatsugi
Misato Hirano
Satoshi Nagayama
Koji Ando
Original Assignee
Pfizer
Renovis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Renovis Inc filed Critical Pfizer
Application granted granted Critical
Publication of ATE509925T1 publication Critical patent/ATE509925T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT07825705T 2006-11-17 2007-11-09 Substituierte bicyclocarbonsäureamidverbindungen ATE509925T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86628506P 2006-11-17 2006-11-17
US94393307P 2007-06-14 2007-06-14
US98334307P 2007-10-29 2007-10-29
PCT/IB2007/003559 WO2008059370A2 (en) 2006-11-17 2007-11-09 Substituted bicyclocarboxyamide compounds

Publications (1)

Publication Number Publication Date
ATE509925T1 true ATE509925T1 (de) 2011-06-15

Family

ID=39311049

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07825705T ATE509925T1 (de) 2006-11-17 2007-11-09 Substituierte bicyclocarbonsäureamidverbindungen

Country Status (12)

Country Link
US (1) US7964732B2 (enExample)
EP (1) EP2091944B1 (enExample)
JP (1) JP2010510202A (enExample)
AR (1) AR064253A1 (enExample)
AT (1) ATE509925T1 (enExample)
CA (1) CA2669915C (enExample)
CL (1) CL2007003289A1 (enExample)
GT (1) GT200700103A (enExample)
PE (1) PE20081504A1 (enExample)
TW (1) TW200831089A (enExample)
UY (1) UY30723A1 (enExample)
WO (1) WO2008059370A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8946204B2 (en) 2009-05-07 2015-02-03 Gruenenthal Gmbh Substituted phenylureas and phenylamides as vanilloid receptor ligands
AU2010244684B2 (en) * 2009-05-07 2014-07-03 Grunenthal Gmbh Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands
ES2640257T3 (es) * 2009-05-07 2017-11-02 Medifron Dbt Inc. Fenilureas y fenilamidas sustituidas como ligandos del receptor vanilloide
WO2012025469A1 (en) * 2010-08-24 2012-03-01 Solvay Sa Improved process for the preparation of esters of 1-h-pyrazole-4-carboxylic acids
US20120115893A1 (en) * 2010-11-10 2012-05-10 Gruenenthal Gmbh Substituted Bicyclic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands
JP5140776B1 (ja) * 2012-09-05 2013-02-13 タマ化学工業株式会社 １−置換−３−フルオロアルキルピラゾール−４−カルボン酸エステルの製造方法
ES2824119T3 (es) 2015-05-18 2021-05-11 Shenyang Sinochem Agrochemicals R & D Co Ltd Compuestos de pirazol sustituidos que contienen pirimidina, y método de preparación y uso de los mismos como pesticidas
AR112673A1 (es) 2017-08-11 2019-11-27 Syngenta Participations Ag Derivados de pirazol activos como plaguicidas
WO2020164993A1 (en) 2019-02-13 2020-08-20 Syngenta Crop Protection Ag Pesticidally active pyrazole derivatives
WO2020164994A1 (en) 2019-02-13 2020-08-20 Syngenta Crop Protection Ag Pesticidally active pyrazole derivatives
CN110256342B (zh) * 2019-07-16 2022-06-07 河南省科学院化学研究所有限公司 一种2-氰基喹啉衍生物的合成方法
CN110734401A (zh) * 2019-10-10 2020-01-31 长沙麓兴生物科技有限公司 一种氮未取代-4-甲酰基吡唑的制备方法
CN114989546B (zh) * 2022-07-05 2023-07-28 上海乐纯生物技术有限公司 一种用于细胞治疗储液袋生产的fep膜
WO2025172368A1 (en) 2024-02-13 2025-08-21 Syngenta Crop Protection Ag (5-isoxazol-3-yl)-[4-(pyrazol-4-yl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone derivatives for use as fungicides
WO2025191053A1 (en) 2024-03-14 2025-09-18 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2025210095A1 (en) 2024-04-03 2025-10-09 Syngenta Crop Protection Ag Microbiocidal tetrahydroisoquinoline compounds
WO2026022173A1 (en) 2024-07-26 2026-01-29 Syngenta Crop Protection Ag Microbiocidal pyrazole compounds

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2671059B2 (ja) 1990-11-30 1997-10-29 富士レビオ株式会社 ナフトエ酸誘導体
AU5006693A (en) 1992-08-07 1994-03-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Polyhydroxylated naphthyl 2-carboxylate, and quinolyl and isoquinolyl 3-carboxylate derivatives as protein tyrosine kinase inhibitors
CA2150345A1 (en) 1993-09-28 1995-04-06 Makoto Komatsu Quinoxaline derivative as antidiabetic agent
DE4423353A1 (de) * 1994-07-04 1996-01-11 Bayer Ag Verfahren zur Herstellung N-acylierter 2-Chlor-5-aminomethylpyridine
US5753700A (en) 1994-12-28 1998-05-19 Ono Pharmaceutical Co., Ltd. Naphthyloxyacetic acid derivatives
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US6979686B1 (en) * 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
WO1999024442A1 (en) 1997-11-12 1999-05-20 Ariad Pharmaceuticals, Inc. Novel signal transduction inhibitors, compositions containing them
CA2311131A1 (en) 1997-11-21 1999-06-03 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists for treating central nervous system diseases
WO2000042213A1 (en) 1999-01-13 2000-07-20 The Research Foundation Of State University Of New York A novel method for designing protein kinase inhibitors
AU3033500A (en) 1999-01-15 2000-08-01 Agouron Pharmaceuticals, Inc. Non-peptide glp-1 agonists
AU781266B2 (en) 1999-04-28 2005-05-12 Sanofi-Aventis Deutschland Gmbh Di-aryl acid derivatives as PPAR receptor ligands
JP2003500387A (ja) 1999-05-24 2003-01-07 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子の阻害剤
JP2003500480A (ja) 1999-06-02 2003-01-07 エヌピーエス ファーマシューティカルズ インコーポレーテッド 代謝型グルタミン酸受容体アンタゴニストおよび中枢神経系の疾病を治療するためのその使用
CA2375920A1 (en) 1999-06-14 2000-12-21 Eli Lilly And Company Compounds
AU5546000A (en) 1999-06-14 2001-01-02 Protherics Molecular Design Limited Compounds
ATE267803T1 (de) * 1999-08-07 2004-06-15 Boehringer Ingelheim Pharma Carbonsäureamide, deren herstellung und deren verwendung als arzneimittel
DE19963179B4 (de) 1999-12-27 2009-02-05 Grünenthal GmbH Substituierte 1- und 2-Naphthol-Mannichbasen
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
DE60133743T2 (de) 2000-08-21 2009-07-02 Pacific Corp. Neue thiourea-derivate und pharmazeutische zusammensetzungen die diese enthalten
HU227197B1 (en) 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
EP1390034A4 (en) 2001-04-03 2005-07-13 Merck & Co Inc N-SUBSTITUTED NONARYL HETEROCYCLO AMIDYL-NMDA / NR2B ANTAGONISTS
WO2002085908A1 (en) 2001-04-24 2002-10-31 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
TWI239942B (en) 2001-06-11 2005-09-21 Dainippon Pharmaceutical Co N-arylphenylacetamide derivative and pharmaceutical composition containing the same
FR2827599A1 (fr) 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
WO2003014064A1 (en) 2001-07-31 2003-02-20 Bayer Healthcare Ag Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists
CA2462289C (en) 2001-10-04 2010-02-23 Nicholas D. Cosford Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
EP1438973A4 (en) * 2001-10-05 2005-07-13 Ono Pharmaceutical Co MEANS FOR THE TREATMENT OF STRESS-RELATED DISEASES WITH MITOCHONDRIENE BENZODIAZEPINE RECEPTOR ANTAGONISTS
US7129225B2 (en) 2001-10-22 2006-10-31 The Research Foundation Of State University Of New York Protection against and treatment of hearing loss
WO2003045920A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 4-aminoquinoline compounds
EP2033953A1 (en) 2002-02-15 2009-03-11 Glaxo Group Limited Vanilloid receptor modulators
US8163769B2 (en) 2002-03-12 2012-04-24 Abbott Laboratories Antibacterial compounds
TW200306159A (en) * 2002-03-19 2003-11-16 Du Pont Bicyclic fused pyridinyl amides and advantageous compositions thereof for use as fungicides
GB0206876D0 (en) 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
JP4595059B2 (ja) 2002-04-18 2010-12-08 株式会社医薬分子設計研究所 アミド誘導体
CN1675154A (zh) 2002-06-07 2005-09-28 科蒂科股份有限公司 抑制巨噬细胞移动抑制因子(mif)的细胞因子或生物活性的萘衍生物
GB2389580A (en) 2002-06-12 2003-12-17 Bayer Ag 2-Naphthamide PGI2 antagonists
WO2004019933A1 (en) 2002-08-30 2004-03-11 Pharmacia & Upjohn Company Method of preventing or treating atherosclerosis or restenosis
EP1581510A4 (en) 2002-11-22 2006-08-30 Bristol Myers Squibb Co 1-ARYL-2-HYDROXYETHYLAMIDEALS CALIUM CHANNEL OPENER
WO2004047739A2 (en) 2002-11-22 2004-06-10 Bristol-Myers Squibb Company Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers
US7179427B2 (en) * 2002-11-25 2007-02-20 Abb Lummus Global Inc. Apparatus for countercurrent contacting of gas and solids
WO2004052371A2 (en) 2002-12-11 2004-06-24 7Tm Pharma A/S Cyclic quinoline compounds for use in mch receptor related disorders
BR0317430A (pt) 2002-12-20 2005-10-25 Pharmacia Corp Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno
ES2401079T3 (es) 2002-12-20 2013-04-16 Amgen Inc. Moduladores del asma y de la inflamación alérgica
EP2308848A1 (en) 2003-02-03 2011-04-13 Janssen Pharmaceutica NV Quinoline-derived amide modulators of vanilloid VR1 receptor
WO2004078114A2 (en) 2003-02-28 2004-09-16 Encysive Pharmaceuticals Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists.
EP1601357A4 (en) 2003-03-10 2007-10-03 Schering Corp HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS
CA2525168A1 (en) 2003-05-14 2004-12-02 Emisphere Technologies, Inc. Compositions for delivering peptide yy and pyy agonists
WO2004108133A2 (en) 2003-06-05 2004-12-16 Vertex Pharmaceuticals Incorporated Modulators of vr1 receptor
CA2529154C (en) 2003-06-20 2013-05-07 Galderma Research & Development, S.N.C. Novel compounds that modulate ppar.gamma. type receptors, and use thereof in cosmetic or pharmaceutical compositions
KR100707123B1 (ko) 2003-07-02 2007-04-16 그뤼넨탈 게엠베하 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 4-(메틸설포닐아미노)페닐 동족체 및 이를함유하는 약학적 조성물
CA2532064A1 (en) 2003-07-15 2005-02-03 Merck & Co., Inc. Hydroxypyridine cgrp receptor antagonists
SE0302323D0 (sv) * 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
JP2007504121A (ja) 2003-08-29 2007-03-01 ファイザー・インク 新たな抗血管形成剤として有用なナフタレン・カルボキサミド及びその誘導体
US20050232818A1 (en) * 2003-09-19 2005-10-20 Donald Sandell Single sheet seal applicator and cartridge
JP4795022B2 (ja) * 2003-09-30 2011-10-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環化合物を含有する新規な抗真菌剤
WO2005035526A1 (en) 2003-10-09 2005-04-21 Argenta Discovery Ltd. Bicyclic compounds and their therapeutic use
JP2007524673A (ja) * 2004-01-23 2007-08-30 アムジエン・インコーポレーテツド バニロイド受容体リガンドと治療におけるその使用
US7544803B2 (en) * 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
CA2553966A1 (en) * 2004-01-23 2005-08-04 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2005087742A1 (en) 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
ZA200609259B (en) 2004-04-30 2008-07-30 Takeda Pharmaceutical Heterocyclic amide compound and use thereof as an mmp-13 inhibitor
WO2006016548A1 (ja) 2004-08-09 2006-02-16 Eisai R & D Management Co., Ltd. ヘテロ環化合物を含有する新規な抗マラリア剤

Also Published As

Publication number Publication date
GT200700103A (es) 2008-11-04
US20100267769A1 (en) 2010-10-21
PE20081504A1 (es) 2008-10-30
WO2008059370A2 (en) 2008-05-22
TW200831089A (en) 2008-08-01
UY30723A1 (es) 2008-07-03
EP2091944A2 (en) 2009-08-26
WO2008059370A3 (en) 2008-07-24
AR064253A1 (es) 2009-03-25
JP2010510202A (ja) 2010-04-02
US7964732B2 (en) 2011-06-21
CA2669915A1 (en) 2008-05-22
CA2669915C (en) 2012-02-07
WO2008059370A8 (en) 2009-06-04
EP2091944B1 (en) 2011-05-18
CL2007003289A1 (es) 2008-06-20

Similar Documents

Publication Publication Date Title
LTC2004635I2 (lt) Pakeistieji enaminokarbonilo junginiai
ATE509925T1 (de) Substituierte bicyclocarbonsäureamidverbindungen
PT2097111E (pt) Heterodímeros de ácido glutámico
ATE524477T1 (de) Aziridinylepothilonverbindungen
BRPI0922904A2 (pt) "compostos"
ATE502948T1 (de) Substituierte bicyclolactamverbindungen
EP1985620A4 (en) COMPOUND 10a-AZALIDE
BRPI0719204A2 (pt) Inibidores de hdac
DK2041139T3 (da) Farmaceutiske forbindelser
BRPI0813500A2 (pt) Compostos antivirais
BRPI0714512A2 (pt) Compostos químicos
EP2298731A4 (en) AMIDE COMPOUND
BRPI0821086A2 (pt) Compostos inseticidas
HRP20190509T1 (hr) Spoj piridilaminooctene kiseline
ATE478849T1 (de) 4-anilinochinolin-3-carbonsäureamide als csf-1r- kinaseinhibitoren
BRPI0811264A2 (pt) Compostos
BRPI0809996A2 (pt) Compostos
EP2275414A4 (en) Cyclopentylacrylic acid amide derivative
BRPI0814424A2 (pt) Compostos heterociclila
BRPI0815332A2 (pt) Composto de ácido fenilacético
DE602007011911D1 (de) Stark hydrophober verbundstoff
BRPI0815181A2 (pt) Compostos
DE602007012490D1 (de) Herbizidzusammensetzung
DK2016067T3 (da) Insecticidforbindelser
BRPI0814613A2 (pt) Compostos

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties